抗精神病薬市場：現状分析・予測 (2021年～2027年)

世界の抗精神病薬の市場規模は予測期間中に7.3%の大幅なCAGRを記録すると予想されています。

高齢化社会の進展、統合失調症や双極性障害などの精神疾患の人口増加、消費者の精神衛生に関する意識などの要因から、大きな成長を示しています。

当レポートでは、世界の抗精神病薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、法規制環境、需給動向、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法・前提因子

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 抗精神病薬市場：COVID-19の影響

第6章 抗精神病薬市場：収益の推移・予測

第7章 市場の洞察：治療クラス別

• 初代
• 第2世代
• 第3世代

第8章 市場の洞察：用途別

• 統合失調症
• 認知症
• 双極性障害
• うつ
• その他

第9章 市場の洞察：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第10章 市場の洞察：地域別

• 北米
• 欧州
• アジア太平洋
• その他の地域

第11章 抗精神病薬市場：市場力学

• 市場促進要因
• 市場課題
• 影響分析

第12章 抗精神病薬市場：市場機会

第13章 抗精神病薬市場：動向

第14章 政策・法規制の枠組み

第15章 需要サイド・供給サイドの分析

• 需要サイド分析
• 供給サイド分析

第16章 バリューチェーン分析

第17章 競合シナリオ

• 競合情勢

第18章 企業プロファイル

• Eli Lily and Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Johnson & Johnson
• Otsuka Pharmaceutical Co, Ltd.
• Pfizer Inc.
• AbbVie Inc.
• Bristol-Myers Squibb
• Teva Pharmaceuticals
• Dr. Reddy's Laboratories

第19章 免責事項

The global antipsychotic drugs market is experiencing significant growth due to the increasing aging population, mental health disorders such as schizophrenia and bipolar disorder amongst the population, and awareness regarding the mental health among consumers. In March 2020 Dr. Reddy's Laboratories announced the launch of Ziprasidone Mesylate for injection, 20 mg (base)/ml single-dose vials, which is the generic therapeutic equivalent of Pfizer's Geodon injection, in the United States. The ziprasidone injection is used to treat occurrences of severe agitation in patients with schizophrenia. Thus, it works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. Furthermore, ziprasidone injection is used when quick relief of your symptoms is required. Therefore, the market for antipsychotic drugs is expected to witness a significant CAGR of 7.3% during the forecast period.

Global antipsychotic drugs market is expected to register a significant CAGR of around 6% over the period of 2021-2027. This is mainly due to the high prevalence of neurological disorders and stringent government regulations coupled with the growing focus of major stakeholders in the healthcare system to adopt to make antipsychotic drug products more sustainable with fewer side effects and eco-friendlier. Major healthcare companies are investing heavily in their products due to rising infertility cases, an increase in the demand for at-home diagnostic devices, awareness of healthcare expenditure, and the rising incidence of gynecological disorders. For instance, according to the World Health Organization (WHO), in 2018, globally more than 300 million individuals suffered from depression. The considerably large number of people suffering from mental stress increases the demand for antipsychotic drugs. As a result, the government is focusing on raising awareness about the illnesses and the effect which significantly contributes to the market for antipsychotic drugs. Therefore, the market for antipsychotic drugs is expected to witness significant growth during the forecast period

Eli Lily and Company, AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, Otsuka Pharmaceutical Co, Ltd., Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, Teva Pharmaceuticals, Dr. Reddy's Laboratories are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst Therapeutic class, second generation category accounted for the majority share in the market in 2020"

Based on therapeutic class, the market is classified into first generation, second generation, and third generation. Amongst types, the second-generation category accounted for a significant share of the market. This is mainly due to this segment dominance is attributable to the presence of a large number of second-generation antipsychotic drugs in the global markets. Over the forthcoming years, the rising popularity of mental health disorders among the younger generation is likely to boost the demand for antipsychotic drugs.

"Amongst Application, schizophrenia is expected to witness highest CAGR during the forecast period"

Based on product, the market is categorized into schizophrenia, dementia, bipolar disorder, depression, and others. Among these, schizophrenia is expected to witness the highest CAGR during the forecast period. Schizophrenia is affecting a large number of people and is expected to support the growth of the segment over the forecast period. For instance, as per WHO, Schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults. These results in serious mental illnesses that affect how a person thinks, feels, and behaves. The continuous development of the new products and procedures is likely to strengthen the market of the segment during the forecast period

"North America to witness significant growth during the forecast period"

North America is expected to show significant growth in the antipsychotic drugs market. The major contributors to the growth of this market are US and Canada. The increase in technology development in emerging economies, as well as the expansion of the healthcare industry, has contributed to the growth of the North America market. North America has a higher adoption rate of technologically advanced and innovative solutions and drugs. The enhanced mental awareness regarding the availability of various antipsychotic drugs has propelled the growth of the market in the region. Furthermore, increasing geriatric population and new product launches, and various developmental strategies adopted by the regional market will drive market growth. The endorsement of increasing demand for mental health awareness campaigns also significantly contributed to the considerable growth of the state. As per the national alliance on mental illness, about 1 in 5 U.S. adults experience mental illness each year.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

Global antipsychotic drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Antipsychotic Drugs Market
• 2.2. Research Methodology of the Antipsychotic Drugs Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Antipsychotic Drugs Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ANTIPSYCHOTIC DRUGS MARKET COVID-19 IMPACT

6 GLOBAL ANTIPSYCHOTIC DRUGS MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY THERAPEUTIC CLASS

• 7.1. First Generation
• 7.2. Second Generation
• 7.3. Third Generation

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Schizophrenia
• 8.2. Dementia
• 8.3. Bipolar Disorder
• 8.4. Depression
• 8.5. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. UK
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. Rest of Asia-Pacific
• 10.4. Rest of World

11 ANTIPSYCHOTIC DRUGS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 ANTIPSYCHOTIC DRUGS MARKET OPPORTUNITIES

13 ANTIPSYCHOTIC DRUGS MARKET TRENDS

14 POLICY & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. Eli Lily and Company
• 18.2. AstraZeneca plc
• 18.3. GlaxoSmithKline plc
• 18.4. Johnson & Johnson
• 18.5. Otsuka Pharmaceutical Co, Ltd.
• 18.6. Pfizer Inc.
• 18.7. AbbVie Inc.
• 18.8. Bristol-Myers Squibb
• 18.9. Teva Pharmaceuticals
• 18.10. Dr. Reddy's Laboratories

19 DISCLAIMER